<code id='AC17DB72F3'></code><style id='AC17DB72F3'></style>
    • <acronym id='AC17DB72F3'></acronym>
      <center id='AC17DB72F3'><center id='AC17DB72F3'><tfoot id='AC17DB72F3'></tfoot></center><abbr id='AC17DB72F3'><dir id='AC17DB72F3'><tfoot id='AC17DB72F3'></tfoot><noframes id='AC17DB72F3'>

    • <optgroup id='AC17DB72F3'><strike id='AC17DB72F3'><sup id='AC17DB72F3'></sup></strike><code id='AC17DB72F3'></code></optgroup>
        1. <b id='AC17DB72F3'><label id='AC17DB72F3'><select id='AC17DB72F3'><dt id='AC17DB72F3'><span id='AC17DB72F3'></span></dt></select></label></b><u id='AC17DB72F3'></u>
          <i id='AC17DB72F3'><strike id='AC17DB72F3'><tt id='AC17DB72F3'><pre id='AC17DB72F3'></pre></tt></strike></i>

          Wikipedia

          Wikipedia

          author:fashion    Page View:77
          Closeup of a human brain affected by Alzheimer's disease, on display at the Museum of Neuroanatomy at the University at Buffalo in Buffalo, N.Y.
          A brain affected by Alzheimer's disease, at the Museum of Neuroanatomy at the University at Buffalo. David Duprey/AP

          Investigators on Wednesday released the first detailed case report about a patient who died after receiving lecanemab, providing a new glimpse into safety concerns surrounding the closely watched experimental Alzheimer’s drug.

          An unpublished version of the report was previously written about by Science in November, one of three deaths from the lecanemab trials revealed by Science and STAT. But the published version, in the New England Journal of Medicine, will allow doctors to evaluate the case as they consider whether and how to use a treatment that could be approved by the FDA as soon as this week.  

          advertisement

          This “will have greater impact on clinicians because it is peer-reviewed and published in the New England Journal,” said Lon Schneider, an Alzheimer’s expert at University of Southern California, who was not affiliated with the work.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          focus

          FDA approval of Sarepta Duchenne genetic therapy gives me hope
          FDA approval of Sarepta Duchenne genetic therapy gives me hope

          Duchennemusculardystrophyhistopathology.Dr.EdwinP.Ewing,Jr./CDCWhenIwasdiagnosedwithDuchennemuscular

          read more
          Biden has enormous polling lead in Democratic primary, despite challenge from RFK Jr.
          Biden has enormous polling lead in Democratic primary, despite challenge from RFK Jr.

          2:42PresidentJoeBidenspeaksintheEastRoomoftheWhiteHouseinWashington,July25,2023.SusanWalsh/APPreside

          read more
          Sports medicine is finally prioritizing gender equality
          Sports medicine is finally prioritizing gender equality

          MollyFergusonforSTATWhencyclistAlisonTetrickjoinedthesport’sprofessionalranks,shereceivedtheperkstha

          read more

          Gilead acquiring CymaBay and its liver disease drug for $4.3 billion

          YichuanCao/SipaUSAGileadSciencessaidMondayitwillacquireCymaBayTherapeuticsfor$4.3billion,addinganewt